| Accession Number | 0001193125-26-281461 |
|---|---|
| Form Type | 4 |
| Filing Date | Jun 24, 2026 |
| Document | View SEC Filing |
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
SVP, Drug Discovery | Common Stock | โ | Jun 22, 2026 | Exercise/Conversion | 10,529 | $2.76 | $29,060.04 | 106,941 | Direct | โ | View Details | |
SVP, Drug Discovery | Common Stock | โ | Jun 22, 2026 | Exercise/Conversion | 4,471 | $11.70 | $52,310.70 | 111,412 | Direct | โ | View Details | |
SVP, Drug Discovery | Common Stock | โ | Jun 22, 2026 | Sale | 8,000 | $35.10 | $280,800.80 | 103,412 | Direct | โ | View Details | |
SVP, Drug Discovery | Common Stock | โ | Jun 22, 2026 | Sale | 7,000 | $35.97 | $251,780.90 | 96,412 | Direct | โ | View Details | |
SVP, Drug Discovery | Stock Option (Right to Buy) | Derivative | Jun 22, 2026 | Exercise/Conversion | 10,529 | $0.00 | $0.00 | 10,376 | Direct | โ | View Details | |
SVP, Drug Discovery | Stock Option (Right to Buy) | Derivative | Jun 22, 2026 | Exercise/Conversion | 4,471 | $0.00 | $0.00 | 25,529 | Direct | โ | View Details |